IN8BIO, INC. - INAB

Sector: Healthcare · Industry: Biological Products, (No Diagnostic Substances)
Website: No information yet · Social: No information yet

Company profile

Powered by TradingView

Quarter snapshot

Latest / Compare
Q1 2026 · Q4 2025
Value (USD)
Total reported value ($000)
$5.502M
QoQ value delta ($000)
-$1.939M (-26.06%)
Implied price effect (QoQ)
-35.23%
Shares
Total shares
3,685,058
QoQ shares delta
+457,335 (+14.17%)
Total shares held by funds (by quarter)

Market chart (INAB)

Powered by TradingView
Interactive chart by TradingView.

Top holders (Q1 2026)

Top 25 only Full list
Partial Q1 2026 data: 17 holders have filed so far. Prior holders are carried forward until their next 13F confirms a change.
Manager Value ($000) Shares % of 13F
Alyeska Investment Group, L.P. 1,397 944,319 0.0%
FRANKLIN RESOURCES INC 1,353 914,531 0.0%
683 Capital Management, LLC 1,072 724,637 0.06%
Stonepine Capital Management, LLC 981 663,412 0.39%
BIOS Capital Management, LP 248 167,805 0.47%
GEODE CAPITAL MANAGEMENT, LLC 127 86,239 0.0%
TWO SIGMA ADVISERS, LP 85 36,351 0.0%
VANGUARD GROUP INC 66 28,348 0.0%
CAPTRUST FINANCIAL ADVISORS 49 33,295 0.0%
Texas Capital Bank Wealth Management Services Inc 35 23,750 0.0%
OPPENHEIMER & CO INC 35 24,033 0.0%
NORTHERN TRUST CORP 30 20,440 0.0%
XTX Topco Ltd 18 12,433 0.0%
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO 4 2,785 0.0%
JONES FINANCIAL COMPANIES LLLP 1 768 0.0%
Tower Research Capital LLC (TRC) 1 1,265 0.0%
UBS Group AG 0 480 0.0%
Rockefeller Capital Management L.P. 0 83 0.0%
BlackRock, Inc. 0 84 0.0%